Labcorp adds new COVID-19 antigen test to repertoire

By staff writers

February 18, 2021 -- Labcorp has added a new high sensitivity antigen test for screening for active COVID-19 disease to its testing offerings. The nasal swab test was developed by DiaSorin.

The test is called Liaison SARS-CoV-2, and it was cleared by the U.S. Food and Drug Administration (FDA) in October of 2020. The test is available through a doctor's order, Labcorp said. Results are available within 24 to 48 hours.

CDC awards Labcorp SARS-CoV-2 sequencing contract
The U.S. Centers for Disease Control and Prevention (CDC) has awarded Labcorp a contract to provide genomic sequencing of samples of the SARS-CoV-2 virus.
Labcorp gets EUA for Pixel at-home COVID-19 kits
Labcorp has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration for Pixel by Labcorp, a kit that will enable users...
Labcorp revenue, earnings surge in Q3
Revenue gains from COVID-19 testing helped propel Labcorp to a 33% increase in revenue in its third quarter. The company said that revenue climbed due...
Labcorp debuts combined COVID-19, flu, and RSV test
Labcorp has launched a combined test for COVID-19, influenza A/B, and respiratory syncytial virus (RSV). The single-panel test is now available throughout...
FDA clears DiaSorin's Simplexa varicella-zoster virus test
DiaSorin Molecular's Simplexa DNA swab test for the varicella-zoster virus is now cleared by the U.S. Food and Drug Administration (FDA).

Copyright © 2021

Last Updated ls 2/18/2021 1:40:14 PM